Antiva Biosciences, Inc.
Antiva Biosciences is a clinical stage biopharmaceutical company dedicated to developing innovative topical antiviral therapies for HPV-related diseases, including persistent high-risk HPV infections and pre-cancerous cervical lesions. Their mission is to provide non-surgical, self-administered treatments to improve health outcomes and support global cervical cancer elimination efforts.
Industries
Nr. of Employees
small (1-50)
Antiva Biosciences, Inc.
Del Mar, California, United States, North America
Products
Development-stage topical intravaginal antiviral prodrug therapy (non-branded)
A development-stage, self-administered topical intravaginal insert using lipophilic prodrug chemistry intended to deliver a nucleotide-analog prodrug to epithelial cells to treat persistent high-risk HPV infection and pre-cancerous cervical intraepithelial neoplasia (CIN 2,3).
Development-stage topical intravaginal antiviral prodrug therapy (non-branded)
A development-stage, self-administered topical intravaginal insert using lipophilic prodrug chemistry intended to deliver a nucleotide-analog prodrug to epithelial cells to treat persistent high-risk HPV infection and pre-cancerous cervical intraepithelial neoplasia (CIN 2,3).
Services
Clinical development and trial execution
Execution of early-stage clinical trials including Phase 1 safety/PK studies and Phase 1b/2 randomized and open-label studies for women with persistent high-risk HPV infection and CIN 2/3.
Topical formulation and drug-delivery development
Development of self-administered intravaginal insert formulations and formulation strategies to achieve local epithelial delivery with minimal systemic exposure.
Regulatory strategy and pharmacovigilance support
Medical safety leadership and pharmacovigilance oversight to support regulatory filings and global development programs.
Program, portfolio and project management
Establishment and operation of program management offices to align cross-functional teams and execute complex development portfolios.
Clinical development and trial execution
Execution of early-stage clinical trials including Phase 1 safety/PK studies and Phase 1b/2 randomized and open-label studies for women with persistent high-risk HPV infection and CIN 2/3.
Topical formulation and drug-delivery development
Development of self-administered intravaginal insert formulations and formulation strategies to achieve local epithelial delivery with minimal systemic exposure.
Regulatory strategy and pharmacovigilance support
Medical safety leadership and pharmacovigilance oversight to support regulatory filings and global development programs.
Program, portfolio and project management
Establishment and operation of program management offices to align cross-functional teams and execute complex development portfolios.
Expertise Areas
- Clinical trial management
- Topical formulation development
- Antiviral drug discovery and virology
- Preclinical and nonclinical development
Key Technologies
- Lipophilic prodrug chemistry for nucleotide analog delivery
- Topical intravaginal insert formulation
- Non-systemic topical drug delivery
- Host-targeted antiviral mechanism (DNA polymerase inhibition)